Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Honghui Zhou

Showing results (71-80 of 143) with videos related to

Pageof 15
Sort By:
The Journal of Investigative Dermatology|March 10, 2019
Immunogenicity of Guselkumab Is Not Clinically Relevant in Patients with Moderate-to-Severe Plaque PsoriasisYaowei Zhu, Joseph C Marini, Michael Song, et al.
Journal of Pharmacokinetics and Pharmacodynamics|March 18, 2018
A comprehensive evaluation of exposure-response relationships in clinical trials: application to support guselkumab dose selection for patients with psoriasisChuanpu Hu, Zhenling Yao, Yang Chen, et al.
Journal of Pharmacokinetics and Pharmacodynamics|June 18, 2017
Challenges in longitudinal exposure-response modeling of data from complex study designs: a case study of modeling CDAI score for ustekinumab in patients with Crohn's diseaseChuanpu Hu, Omoniyi J Adedokun, Yang Chen, et al.
Journal of Pharmacokinetics and Pharmacodynamics|July 2, 2018
Joint longitudinal model development: application to exposure-response modeling of ACR and DAS scores in rheumatoid arthritis patients treated with sirukumabChuanpu Hu, Yan Xu, Yanli Zhuang, et al.
Journal of Clinical Pharmacology|March 24, 2007
Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical developmentMary Ann Mascelli, Honghui Zhou, Raymond Sweet, et al.
Clinical Pharmacology and Therapeutics|September 1, 2020
Extrapolating Pharmacodynamic Effects From Adults to Pediatrics: A Case Study of Ustekinumab in Pediatric Patients With Moderate to Severe Plaque PsoriasisWangda Zhou, Chuanpu Hu, Yaowei Zhu, et al.
Journal of Clinical Pharmacology|April 15, 2023
Model-Based Investigation of Inadequate Efficacy of Tesnatilimab, an Anti-Natural Killer Group 2 Member D Monoclonal Antibody, in Moderately to Severely Active Crohn DiseaseJie Zhou, Yan Xu, Yang Chen, et al.
Clinical Biochemistry|September 15, 2025
Reliable LC-MS/MS method development and validation for the determination of methylmalonic acid, methylcitric acid, malonic acid, ethylmalonic acid, and total homocysteine in dried blood spotsChunyan Zhang, Nan Bai, Yanling Yang, et al.
BMC Pediatrics|June 3, 2026
Quality and consistency of genetic newborn screening reports in China: insights from a multi-laboratory analysis using simulated samplesJiaming Wu, Penghui Feng, Jinming Zhang, et al.
Clinical and Translational Science|October 7, 2022
Population-based cellular kinetic characterization of ciltacabtagene autoleucel in subjects with relapsed or refractory multiple myelomaLiviawati S Wu, Yaming Su, Claire Li, et al.
Pageof 15

Showing results (71-80 of 143) with videos related to

Sort By:
Pageof 15
The Journal of Investigative Dermatology|March 10, 2019
Immunogenicity of Guselkumab Is Not Clinically Relevant in Patients with Moderate-to-Severe Plaque PsoriasisYaowei Zhu, Joseph C Marini, Michael Song, et al.
Journal of Pharmacokinetics and Pharmacodynamics|March 18, 2018
A comprehensive evaluation of exposure-response relationships in clinical trials: application to support guselkumab dose selection for patients with psoriasisChuanpu Hu, Zhenling Yao, Yang Chen, et al.
Journal of Pharmacokinetics and Pharmacodynamics|June 18, 2017
Challenges in longitudinal exposure-response modeling of data from complex study designs: a case study of modeling CDAI score for ustekinumab in patients with Crohn's diseaseChuanpu Hu, Omoniyi J Adedokun, Yang Chen, et al.
Journal of Pharmacokinetics and Pharmacodynamics|July 2, 2018
Joint longitudinal model development: application to exposure-response modeling of ACR and DAS scores in rheumatoid arthritis patients treated with sirukumabChuanpu Hu, Yan Xu, Yanli Zhuang, et al.
Journal of Clinical Pharmacology|March 24, 2007
Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical developmentMary Ann Mascelli, Honghui Zhou, Raymond Sweet, et al.
Clinical Pharmacology and Therapeutics|September 1, 2020
Extrapolating Pharmacodynamic Effects From Adults to Pediatrics: A Case Study of Ustekinumab in Pediatric Patients With Moderate to Severe Plaque PsoriasisWangda Zhou, Chuanpu Hu, Yaowei Zhu, et al.
Journal of Clinical Pharmacology|April 15, 2023
Model-Based Investigation of Inadequate Efficacy of Tesnatilimab, an Anti-Natural Killer Group 2 Member D Monoclonal Antibody, in Moderately to Severely Active Crohn DiseaseJie Zhou, Yan Xu, Yang Chen, et al.
Clinical Biochemistry|September 15, 2025
Reliable LC-MS/MS method development and validation for the determination of methylmalonic acid, methylcitric acid, malonic acid, ethylmalonic acid, and total homocysteine in dried blood spotsChunyan Zhang, Nan Bai, Yanling Yang, et al.
BMC Pediatrics|June 3, 2026
Quality and consistency of genetic newborn screening reports in China: insights from a multi-laboratory analysis using simulated samplesJiaming Wu, Penghui Feng, Jinming Zhang, et al.
Clinical and Translational Science|October 7, 2022
Population-based cellular kinetic characterization of ciltacabtagene autoleucel in subjects with relapsed or refractory multiple myelomaLiviawati S Wu, Yaming Su, Claire Li, et al.
Pageof 15